Integra LifeSciences/$IART
1D1W1MYTD1Y5YMAX
Capital at risk
About Integra LifeSciences
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
- Ticker
- $IART
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4,427
- Headquarters
- Princeton, United States
- Website
- www.integralife.com
IART Metrics
BasicAdvanced
$1.2B
-
-$0.10
1.22
-
Price and volume
Market cap
$1.2B
Beta
1.22
52-week high
$20.49
52-week low
$8.70
Average daily volume
669K
Financial strength
Current ratio
3.601
Quick ratio
1.636
Long term debt to equity
1.909
Total debt to equity
1.965
Interest coverage (TTM)
1.78%
Profitability
EBITDA (TTM)
316.918
Gross margin (TTM)
56.87%
Net profit margin (TTM)
-0.44%
Operating margin (TTM)
9.92%
Effective tax rate (TTM)
-3,901.10%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
2.85%
Return on equity (TTM)
-0.70%
Valuation
Price to revenue (TTM)
0.724
Price to book
1.15
Price to tangible book (TTM)
-1.87
Price to free cash flow (TTM)
-31.832
Free cash flow yield (TTM)
-3.14%
Free cash flow per share (TTM)
-0.487
Growth
Revenue change (TTM)
1.60%
Earnings per share change (TTM)
-98.47%
3-year revenue growth (CAGR)
2.16%
10-year revenue growth (CAGR)
5.57%
3-year earnings per share growth (CAGR)
-60.17%
10-year earnings per share growth (CAGR)
-2.31%
What the Analysts think about IART
Analyst ratings (Buy, Hold, Sell) for Integra LifeSciences stock.
Analyst projections of the future price of Integra LifeSciences stock.
Bulls say / Bears say
First-quarter 2026 revenue rose 2.4% year-over-year, beating analyst expectations on robust wound reconstruction growth and improved supply reliability. (Reuters)
The company raised its full-year 2026 adjusted EPS outlook to $2.40–$2.50, up from $2.30–$2.40, reflecting management’s confidence in margin expansion and operational leverage. (Reuters)
Appointment of Stuart Essig as President and CEO reinstates seasoned leadership with deep company knowledge, supporting strategic continuity and execution. (Reuters)
Tissue Technologies revenue declined 12.8% in the fourth quarter due to ongoing MediHoney remediation efforts and challenging prior‐year comparables, underscoring portfolio execution risks. (Reuters)
Filing a mixed shelf offering for an unspecified amount signals potential future share dilution and uncertainty around the company’s capital structure. (Reuters)
Second-quarter 2026 revenue grew just 0.8% year-over-year, reflecting continued top-line pressure in a competitive medical‐device market. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2026.
IART Financial Performance
Revenues and expenses
IART Earnings Performance
Company profitability
Upcoming events
No upcoming events
IART News
AllArticlesVideos
Funds containing IART
AllUSDEURGBP
Fund name | Fund size | $IART weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.15% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.15% |
iShares Healthcare Innovation£DRDR | £1B | 0.15% |
iShares Ageing Population€AGED | €822M | 0.12% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.